AccuStem Sciences, Inc. (ACUT)

OTCMKTS: ACUT · Delayed Price · USD
1.30
-0.10 (-7.14%)
Nov 25, 2022 4:00 PM EST - Market closed
-7.14%
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -3.44M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,537
Open 1.45
Previous Close 1.4
Day's Range 1.45 - 1.45
52-Week Range 0.26 - 3
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ACUT

AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York. [Read more]

Industry Biotechnology
Founded 2020
Country United States
Stock Exchange OTCMKTS
Ticker Symbol ACUT
Full Company Profile

News

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

LONDON and PHOENIX, Nov. 22, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that...

1 week ago - GlobeNewsWire

AccuStem Sciences Announces Appointment of Sean McDonald to Board of Directors

LONDON and PHOENIX, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced toda...

2 weeks ago - GlobeNewsWire

AccuStem Announces Adjournment of Annual Meeting of Stockholders

LONDON and PHOENIX, Oct. 10, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today...

1 month ago - GlobeNewsWire

AccuStem Sciences Announces Issuance of US Patent for StemPrintER Test for Patients with Breast Cancer

LONDON and PHOENIX, Ariz., Sept. 13, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announ...

2 months ago - GlobeNewsWire

AccuStem Sciences, Inc. Announces DTC Eligibility

LONDON and PHOENIX, April 14, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to announce its...

7 months ago - GlobeNewsWire

AccuStem Announces Private Placement of Common Stock

LONDON and PHOENIX, April 05, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that it has e...

7 months ago - GlobeNewsWire

AccuStem Sciences, Inc. Appoints New Executive Leadership Team

Company plans to uplist to the Nasdaq Capital Market Company plans to uplist to the Nasdaq Capital Market

8 months ago - GlobeNewsWire